Clinical trials: Adrenal Tumors
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
This phase II trial studies how well anlotinib hydrochloride works in treating patients with metastatic pheochromocytoma or paraganglioma.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Pheochromocytoma, Metastatic, Paraganglioma, Malignant
- Trial name
- NCT04860700
- Testing
- anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Neuroendocrine Tumors, Carcinoid Tumors
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who…
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Adrenal Gland Tumors, Neuroblastoma
- Trial name
- NCT00947167
- Testing
- pertuzumab, erlotinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pamela L. Kunz
Adrenocortical Carcinoma
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01528956
- Testing
- DNA methylation analysis, RNA analysis, gene expression analysis
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Adrenocortical Carcinoma
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
This work will evaluate the adverse effects of mitotane treatment in patients treated for ACC with mitotane therapy. All of the individuals were treated at Ruijin Hospital between May 2023 and May 2024.
- Trial name
- MEET (NCT05839886)
- Volunteers
- 50 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Primary Hyperaldosteronism, Aldosterone-Producing Adenoma
[18F]AlF-NOTA-pentixather PET/CT in Patients With Suspected Primary Hyperaldosteronism
The study was proposed to include 20 patients with clinical suspicion of primary aldosteronism for [18F]AlF-NOTA-pentixather PET/CT imaging and to analyze the specificity and sensitivity of [18F]AlF-NOTA-pentixather PET/CT for…
- Trial name
- NCT05815069
- Testing
- [18F]AlF-NOTA-pentixather PET/CT
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Adrenal Cortical Cancer, Brain Cancer
Spectroscopy With Surface Coils and Decoupling
The purpose of this study is to obtain chemical information from part of your body without a biopsy. This is done using a technique called magnetic resonance spectroscopy (MRS) which is similar to magnetic resonance imaging (MRI)…
- Conditions
- Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00581815
- Testing
- Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
- Where
- United States
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
Primary aldosteronism (PA) is the excessive endogenous production of the mineralocorticoid aldosterone. Although various rare forms of PA exist, the vast majority of cases are accounted by either an aldosterone-producing adenoma…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Primary Aldosteronism Due to Conn Adenoma
- Trial name
- NCT04761354
- Testing
- Unilateral adrenalectomy
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 514 people
- Sponsor
- UMC Utrecht
Outcome Assessment, Adrenal Neoplasm
Textbook Outcome in Adrenal Neoplasms
BACKGROUND: Textbook outcome (TO) is a multidimensional quality management tool that uses a set of traditional surgical measures to reflect an "ideal" surgical result for a particular pathology.
- Trial name
- NCT05888753
- Testing
- Adrenalectomy
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Hospital General Universitario de Alicante
Primary Aldosteronism, Adrenal Tumor
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery.
- Conditions
- Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)
- Trial name
- NCT07182175
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Diagnostic Value of 68Ga-Pentixafor PET/CT in Adrenal Tumors With Aldosterone and Cortisol Cosecretion
The goal of this observational study is to evaluate the diagnostic accuracy of 68 68 Ga-Pentixafor-CXCR4 PET/CT in identifying the dominant side of hormone excess in adult patients (aged 18-80 years) with primary aldosteronism…
- Trial name
- NCT07605156
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University First Hospital
Non Small Cell Lung Cancer, Lung Cancer Stage 1
Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
The purpose of this study is to assess pain management after elective thoracoscopic lobectomy. The study will compare two local anesthetics that are given intra-operatively during lobectomy to see which one helps in better pain…
- Trial name
- BEMP (NCT03682224)
- Testing
- Liposomal Bupivacaine, Bupivacaine-Epinephrine
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Southern Illinois University
Pituitary Adenoma, Adrenal Insufficiency
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.
- Conditions
- Pituitary Adenoma, Adrenal Insufficiency, Surgery
- Trial name
- NCT04621565
- Testing
- Normal saline, Hydrocortisone
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Peking Union Medical College Hospital
Cushing's Syndrome, Ectopic Corticotropin Syndrome
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
- Conditions
- Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma
- Trial name
- NCT02468193
- Testing
- Osilodrostat
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Cancer, Papillary, Primary Aldosteronism
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies.
- Trial name
- NCT06068101
- Testing
- Secreening test for primary aldosteronism and Confirmatory Testing
- Where
- Brazil
- Volunteers
- 274 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Adrenocortical Carcinoma
Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)
This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.
- Trial name
- PESETA (NCT05913427)
- Testing
- Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Hyperandrogenemia, Obesity
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Short term hydrocortisone to test whether improves excess androgen production from adrenal gland and ovaries
- Conditions
- Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
- Trial name
- NCT01422707
- Testing
- Hydrocortisone
- Where
- United States
- Sponsor
- University of Virginia
Adrenal Incidentaloma
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas
The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone…
- Trial name
- NAPACA (NCT04917757)
- Testing
- 1mg Dexamethasone test
- Where
- 2 sites in Germany, Italy
- Volunteers
- 3,656 people
- Sponsor
- Wuerzburg University Hospital
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
This phase II MATCH treatment trial identifies the effects of trametinib in patients whose cancer has genetic changes called GNAQ or GNA11 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439357
- Testing
- Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma
Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%.
- Trial name
- NCT04318730
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- West China Hospital